BI-1569912 is a selective negative allosteric modulator of NR2B-containing NMDA receptors. It is being developed by Boehringer Ingelheim to treat major depressive disorder. As of May 2025, it is in phase 2 clinical trials.
See also List of investigational antidepressants
References